While several groups are exploring the potential of latency reversal agents (LRAs) to eliminate the HIV-1 reservoirs in vivo [57–59], there is an unmet need for therapeutic approaches that can resolve the immune dysfunction in PLWH and induce a robust CD8+ T lymphocyte response necessary to control infection when latency is reversed. The gene discussed is CD8A; the disease is infection.